Regeneron PharmaceuticalsRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Regeneron Pharmaceuticals (REGN) reported revenue of $4.29B in Q2 2026, with Collaboration Revenue its largest revenue segment at 57%.
Regeneron PharmaceuticalsAntibody biotech behind Eylea and Dupixent. Its GLP-1 exposure is complementary rather than competitive: the Phase 2 COURAGE trial adds trevogrumab (anti-myostatin), with or without garetosmab, on top of semaglutide to protect lean mass. At 26 weeks the combination prevented roughly half the lean-mass loss seen with semaglutide alone.
Q3 2024-Q2 2026
Q3 2024-Q2 2026
Q3 2024-Q2 2026
Regeneron Pharmaceuticals (REGN) is a Biotechnology company. Antibody biotech behind Eylea and Dupixent. Its GLP-1 exposure is complementary rather than competitive: the Phase 2 COURAGE trial adds trevogrumab (anti-myostatin), with or without garetosmab, on top of semaglutide to protect lean mass. At 26 weeks the combination prevented roughly half the lean-mass loss seen with semaglutide alone. It was founded in 1988, is headquartered in Tarrytown, NY and employs about 15,410 people.
As of 2026-Q2, Regeneron Pharmaceuticals's revenue breaks down across Collaboration Revenue (57%), Product (38%), Product and Service, Other (5%). See the revenue-by-segment chart for the full mix.
Track Regeneron Pharmaceuticals's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated July 30, 2026.
Sterling groups Regeneron Pharmaceuticals in the GLP-1 sector, alongside Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE), Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).
If you are researching Regeneron Pharmaceuticals, also look at Eli Lilly (LLY), Novo Nordisk (NVO) and Pfizer (PFE). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.